Pyxis Oncology Advances MICVO Toward Phase 3 in HNSCC
BOSTON — September 9, 2026 Pyxis Oncology, Inc. announced positive updated data from its ongoing Phase 1 monotherapy study...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BOSTON — September 9, 2026 Pyxis Oncology, Inc. announced positive updated data from its ongoing Phase 1 monotherapy study...
CAMBRIDGE, UK, May 19, 2026 Cyclana Bio announced that it has received Health Research Authority (HRA) and Research Ethics...
ROSWELL, Ga., Feb. 12, 2026 — StimLabs announced that the U.S. Food and Drug Administration has granted 510(k) clearance...
